Characterization of urinary biomarkers of hepatocellular carcinoma using magnetic resonance spectroscopy in a Nigerian population

Journal of Proteome Research

Volumn 9, Issue 2, 2010, Pages 1096-1103

  Shariff, Mohamed I F ^a   Ladep, Nimzing G ^b   Cox, I Jane ^a   Williams, Horace R T ^a   Okeke, Edith ^b   Malu, Abraham ^c   Thillainayagam, Andrew V ^a   Crossey, Mary M E ^a   Khan, Shahid A ^a   Thomas, Howard C ^a   Taylor Robinson, Simon D ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF JOS   (Nigeria)

^c Hammersmith Hospital Campus ^*

Author keywords

Hepatitis B virus; Hepatocellular carcinoma; Magnetic resonance spectroscopy; Metabonomics; Urinary biomarkers

Indexed keywords

ACETONE; ALANINE AMINOTRANSFERASE; ALBUMIN; ALKALINE PHOSPHATASE; ALPHA FETOPROTEIN; BILIRUBIN; BIOLOGICAL MARKER; CARNITINE; CREATINE; CREATININE; HEPATITIS B SURFACE ANTIGEN; UREA;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; BILIRUBIN BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISCRIMINANT ANALYSIS; FEMALE; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MALE; MULTIVARIATE ANALYSIS; NIGERIA; PARTIAL LEAST SQUARES REGRESSION; PRINCIPAL COMPONENT ANALYSIS; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; SENSITIVITY AND SPECIFICITY; UREA BLOOD LEVEL; URINALYSIS; URINE;

ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; CARCINOMA, HEPATOCELLULAR; CASE-CONTROL STUDIES; COHORT STUDIES; FEMALE; HUMANS; LIVER NEOPLASMS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NIGERIA;

HEPATITIS B VIRUS;

EID: 76149141576     PISSN: 15353893     EISSN: None     Source Type: Journal    
DOI: 10.1021/pr901058t     Document Type: Article

References (42)

1. El-Serag, H. B. Epidemiology of hepatocellular carcinoma in USA. Hepatol. Res. 2007, 37 (Suppl. 2), S88-S94.
2. Taylor-Robinson, S. D.; Foster, G. R.; Arora, S.; Hargreaves, S.; Thomas, H. C. Increase in primary liver cancer in the UK, 1979-94. Lancet 1997, 350 (9085), 1142-1143.
3. Khan, S. A.; Taylor-Robinson, S. D.; Toledano, M. B.; Beck, A.; Elliott, P.; Thomas, H. C. Changing international trends in mortality rates for liver, biliary and pancreatic tumours. J. Hepatol. 2002, 37 (6), 806-813.
4. Beasley, R. P.; Hwang, L. Y.; Lin, C. C.; Chien, C. S. Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22 707 men in Taiwan. Lancet 1981, 2 (8256), 1129-1133.
5. Ladep, N. G.; Taylor-Robinson, S. D. Management of liver disease in Nigeria. Clin. Med. 2007, 7 (5), 439-441.
6. Echejoh, G. O.; Tanko, M. N.; Manasseh, A. N.; Ogala-Echejoh, S.; Ugoya, S. O.; Mandong, B. M. Hepatocellular carcinoma in Jos, Nigeria. Niger. J. Med 2008, 17 (2), 210-213.
7. Yuen, M. F.; Cheng, C. C.; Lauder, I. J.; Lam, S. K.; Ooi, C. G.; Lai, C. L. Early detection of hepatocellular carcinoma increases the chance of treatment: Hong Kong experience. Hepatology 2000, 31 (2), 330-335.
8. Furui, J.; Furukawa, M.; Kanematsu, T. The low positive rate of serum alpha-fetoprotein levels in hepatitis C virus antibodypositive patients with hepatocellular carcinoma. Hepatogastroenterology 1995, 42 (5), 445-449.
9. Nguyen, M. H.; Keeffe, E. B. Screening for hepatocellular carcinoma. J. Clin. Gastroenterol. 2002, 35 (5 Suppl. 2), S86-S91.
10. Peng, Y. C.; Chan, C. S.; Chen, G. H. The effectiveness of serum alpha-fetoprotein level in anti-HCV positive patients for screening hepatocellular carcinoma. Hepatogastroenterology 1999, 46 (30), 3208-3211.
11. Raedle, J.; Roth, W. K.; Oremek, G.; Caspary, W. F.; Zeuzem, S. Alpha-fetoprotein and p53 autoantibodies in patients with chronic hepatitis C. Dig. Dis. Sci. 1995, 40 (12), 2587-2594.
12. Gomaa; Khan, S.; Leen, E.; Waked, I.; Taylor-Robinson, S. D. Diagnosis of Hepatocellular Carcinoma. World J. Gastroenterol., in press.
13. Nicholson, J. K.; Lindon, J. C. Systems biology: Metabonomics. Nature 2008, 455 (7216), 1054-1056.
14. Williams, H. R.; Cox, I. J.; Walker, D. G.; North, B. V.; Patel, V. M.; Marshall, S. E.; Jewell, D. P.; Ghosh, S.; Thomas, H. J.; Teare, J. P.; Jakobovits, S.; Zeki, S.; Welsh, K. I.; Taylor-Robinson, S. D.; Orchard, T. R. Characterization of inflammatory bowel disease with urinary metabolic profiling. Am. J. Gastroenterol. 2009, 104 (6), 1435-1444.
15. Holmes, E.; Loo, R. L.; Stamler, J.; Bictash, M.; Yap, I. K.; Chan, Q.; Ebbels, T.; De, I. M.; Brown, I. J.; Veselkov, K. A.; Daviglus, M. L.; Kesteloot, H.; Ueshima, H.; Zhao, L.; Nicholson, J. K.; Elliott, P. Human metabolic phenotype diversity and its association with diet and blood pressure. Nature 2008, 453 (7193), 396-400.
16. Gao, H.; Dong, B.; Liu, X.; Xuan, H.; Huang, Y.; Lin, D. Metabonomic profiling of renal cell carcinoma: high-resolution proton nuclear magnetic resonance spectroscopy of human serum with multivariate data analysis. Anal. Chim. Acta 2008, 624 (2), 269-277.
17. Gao, H.; Lu, Q.; Liu, X.; Cong, H.; Zhao, L.; Wang, H.; Lin, D. Application of 1H NMR-based metabonomics in the study of metabolic profiling of human hepatocellular carcinoma and liver cirrhosis. Cancer Sci. 2009, 100 (4), 782-785.
18. Bertini, I.; Calabro, A.; De, C. V.; Luchinat, C.; Nepi, S.; Porfirio, B.; Renzi, D.; Saccenti, E.; Tenori, L. The metabonomic signature of celiac disease. J. Proteome Res. 2009, 8 (1), 170-177.
19. Khan, S. A.; Cox, I. J.; Thillainayagam, A. V.; Bansi, D. S.; Thomas, H. C.; Taylor-Robinson, S. D. Proton and phosphorus-31 nuclear magnetic resonance spectroscopy of human bile in hepatopancreaticobiliary cancer. Eur. J. Gastroenterol. Hepatol. 2005, 17 (7), 733-738.
20. Yang, Y.; Li, C.; Nie, X.; Feng, X.; Chen, W.; Yue, Y.; Tang, H.; Deng, F. Metabonomic studies of human hepatocellular carcinoma using high-resolution magic-angle spinning 1H NMR spectroscopy in conjunction with multivariate data analysis. J. Proteome Res. 2007, 6 (7), 2605-2614.
21. Soper, R.; Himmelreich, U.; Painter, D.; Somorjai, R. L.; Lean, C. L.; Dolenko, B.; Mountford, C. E.; Russell, P. Pathology of hepatocellular carcinoma and its precursors using proton magnetic resonance spectroscopy and a statistical classification strategy. Pathology 2002, 34 (5), 417-422.
22. Okuda, K.; Ohtsuki, T.; Obata, H.; Tomimatsu, M.; Okazaki, N.; Hasegawa, H.; et al. Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer 1985, 56 (4), 918-928.
23. Beckonert, O.; Keun, H. C.; Ebbels, T. M.; Bundy, J.; Holmes, E.; Lindon, J. C.; Nicholson, J. K. Metabolic profiling, metabolomic and metabonomic procedures for NMR spectroscopy of urine, plasma, serum and tissue extracts. Nat. Protoc. 2007, 2 (11), 2692-2703.
24. Wishart, D. S.; Tzur, D.; Knox, C.; Eisner, R.; Guo, A. C.; Young, N.; Cheng, D.; Jewell, K.; Arndt, D.; Sawhney, S.; Fung, C.; Nikolai, L.; Lewis, M.; Coutouly, M. A.; Forsythe, I.; Tang, P.; Shrivastava, S.; Jeroncic, K.; Stothard, P.; Amegbey, G.; Block, D.; Hau, D. D.; Wagner, J.; Miniaci, J.; Clements, M.; Gebremedhin, M.; Guo, N.; Zhang, Y.; Duggan, G. E.; Macinnis, G. D.; Weljie, A. M.; Dowlatabadi, R.; Bamforth, F.; Clive, D.; Greiner, R.; Li, L.; Marrie, T.; Sykes, B. D.; Vogel, H. J.; Querengesser, L. HMDB: the Human Metabolome Database. Nucleic Acids Res. 2007, 35 (Database issue), D521-D526.
25. Lindon, J. C.; Holmes, E.; Nicholson, J. K. NMR spectroscopy of biofluids. Annu. Rep. NMR Spectrosc. 1999, 38, 1-88.
26. Trygg, J.; Holmes, E.; Lundstedt, T. Chemometrics in metabonomics. J. Proteome Res. 2007, 6 (2), 469-479.
27. Walsh, M. C.; Brennan, L.; Malthouse, J. P.; Roche, H. M.; Gibney, M. J. Effect of acute dietary standardization on the urinary, plasma, and salivary metabolomic profiles of healthy humans. Am. J. Clin. Nutr. 2006, 84 (3), 531-539.
28. Psihogios, N. G.; Gazi, I. F.; Elisaf, M. S.; Seferiadis, K. I.; Bairaktari, E. T. Gender-related and age-related urinalysis of healthy subjects by NMR-based metabonomics. NMR Biomed. 2008, 21 (3), 195-207.
29. Westerhuis, J.; Hoefsloot, H.; Smit, S.; Vis, D.; Smilde, A.; van Velzen, J.; van Duijnhoven, J.; van Dorsten, F. Assessment of PLSDA cross validation. Metabolomics 2008, 4 (1), 81-89.
30. Mahadevan, S.; Shah, S. L.; Marrie, T. J.; Slupsky, C. M. Analysis of metabolomic data using support vector machines. Anal. Chem. 2008, 80 (19), 7562-7570.
31. Bales, J. R.; Sadler, P. J.; Nicholson, J. K.; Timbrell, J. A. Urinary excretion of acetaminophen and its metabolites as studied by proton NMR spectroscopy. Clin. Chem. 1984, 30 (10), 1631-1636.
32. Man, M. Z.; Dyson, G.; Johnson, K.; Liao, B. Evaluating methods for classifying expression data. J. Biopharm. Stat. 2004, 14 (4), 1065-1084.
33. Barr, D. B.; Wilder, L. C.; Caudill, S. P.; Gonzalez, A. J.; Needham, L. L.; Pirkle, J. L. Urinary creatinine concentrations in the U.S. population: implications for urinary biologic monitoring measurements. Environ. Health Perspect. 2005, 113 (2), 192-200.
34. Rebouche, C. J. Kinetics, pharmacokinetics, and regulation of L-carnitine and acetyl-L-carnitine metabolism. Ann. N.Y. Acad. Sci. 2004, 1033, 30-41.
35. Vaz, F. M.; Wanders, R. J. Carnitine biosynthesis in mammals. Biochem. J. 2002, 361 (Pt. 3), 417-429.
36. Pang, B.; Zhang, H.; Wang, J.; Chen, W. Z.; Li, S. H.; Shi, Q. G.; Liang, R. X.; Xie, B. X.; Wu, R. Q.; Qian, X. L.; Yu, L.; Li, Q. M.; Huang, C. F.; Zhou, J. G. Ubiquitous mitochondrial creatine kinase is overexpressed in the conditioned medium and the extract of LNCaP lineaged androgen independent cell lines and facilitates prostate cancer progression. Prostate 2009, 69 (11), 1176-1187.
37. Bairaktari, E.; Katopodis, K.; Siamopoulos, K. C.; Tsolas, O. Paraquat-induced renal injury studied by 1H nuclear magnetic resonance spectroscopy of urine. Clin. Chem. 1998, 44 (6 Pt. 1), 1256-1261.
38. Bales, J. R.; Higham, D. P.; Howe, I.; Nicholson, J. K.; Sadler, P. J. Use of high-resolution proton nuclear magnetic resonance spectroscopy for rapid multi-component analysis of urine. Clin. Chem. 1984, 30 (3), 426-432.
39. Kalapos, M. P. On the mammalian acetone metabolism: from chemistry to clinical implications. Biochim. Biophys. Acta 2003, 1621 (2), 122-139.
40. Zhao, W. D.; Guan, S.; Zhou, K. R.; Li, H.; Peng, W. J.; Tang, F.; Chen, Z. W. In vivo detection of metabolic changes by 1H-MRS in the DEN-induced hepatocellular carcinoma in Wistar rat. J. Cancer Res. Clin. Oncol. 2005, 131 (9), 597-602.
41. Brereton, R. Consequences of sample size, variable selection, and model validation and optimization, for predicting classification ability from analytical data. Trends Anal. Chem. 2006, 25 (11), 1103-1111.
42. Jelic, S. Hepatocellular carcinoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. ESMO Guidelines Working Group. Ann. Oncol. 2009, 20 (Suppl. 4), 41-45.